Re: 2 new upcoming presentations
|
1
|
Resverlogix Corp.
|
May 02, 2020 09:08PM
|
Re: 2 new upcoming presentations
|
4
|
Resverlogix Corp.
|
May 02, 2020 06:22PM
|
Re: Financial Times article on UCSF Covid project about the 69 potential drugs
|
4
|
Resverlogix Corp.
|
May 01, 2020 10:24PM
|
Re: QBI COVID-19 research results
|
7
|
Resverlogix Corp.
|
Apr 30, 2020 05:14PM
|
Re: Cytokine storm hypothesis takes a hit with the latest IL-6 targeted therapies
|
8
|
Resverlogix Corp.
|
Apr 27, 2020 02:27PM
|
Cytokine storm hypothesis takes a hit with the latest IL-6 targeted therapies
|
5
|
Resverlogix Corp.
|
Apr 27, 2020 12:42PM
|
Re: Article on Epigenetics
|
6
|
Resverlogix Corp.
|
Apr 27, 2020 12:28PM
|
BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs
|
6
|
Resverlogix Corp.
|
Apr 27, 2020 12:05PM
|
Re: Whatever happened to the update on our trial? Stalled like everything else here.
|
5
|
Resverlogix Corp.
|
Apr 23, 2020 09:03PM
|
BET inhibitors induce senolysis
|
5
|
Zenith Epigenetics
|
Apr 23, 2020 07:54AM
|
Re: Bear
|
2
|
Zenith Epigenetics
|
Apr 22, 2020 02:33PM
|
Re: Bear
|
2
|
Zenith Epigenetics
|
Apr 21, 2020 04:13PM
|
Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?
|
2
|
Zenith Epigenetics
|
Apr 19, 2020 01:55PM
|
Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?
|
2
|
Zenith Epigenetics
|
Apr 19, 2020 01:41PM
|
BRD4 Interacts with GATA4 to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes
|
5
|
Resverlogix Corp.
|
Apr 17, 2020 05:15PM
|
Re: Two Interesting Articles - 2 of 2: COVID-19: consider cytokine storm syndromes and immunosuppression
|
5
|
Resverlogix Corp.
|
Apr 13, 2020 05:08PM
|
Re: Random thoughts RVX-208 and COVID-19
|
2
|
Resverlogix Corp.
|
Apr 13, 2020 04:21PM
|
Re: Random thoughts RVX-208 and COVID-19
|
5
|
Resverlogix Corp.
|
Apr 13, 2020 03:36PM
|
Re: New presentation on the website
|
4
|
BIOASIS TECHNOLOGIES INC
|
Apr 11, 2020 06:15PM
|
Re: New presentation on the website
|
2
|
BIOASIS TECHNOLOGIES INC
|
Apr 11, 2020 06:04PM
|